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Arachidonic acid (AA), a metabolite of membrane phospholipids, and its metabolites are increased in Mg2 + deficiency. We examined
whether the extracellular Mg2 + concentration affects AA production and whether AA regulates a putative Na+-dependent Mg2 + efflux
pathway in renal epithelial NRK-52E cells. We used the cells cultured in 5 mM Mg2 +-containing medium for 2 days because they enable us
to detect Na+-stimulated Mg2 + efflux that was not observed in normal culture medium. Removal of extracellular Mg2 + increased AA release
both in the absence and presence of extracellular Na+. This was inhibited by methyl arachidonyl fluorophosphonate (MAFP, 10 AM), an
inhibitor of cytosolic phospholipase A2 (cPLA2) and Ca
2 +-independent phospholipase A2 (iPLA2), and bromoenol lactone (BEL, 10 AM), an
inhibitor of iPLA2. However, LY-311727 (10 AM), a secretory phospholipase A2 (sPLA2) inhibitor, had no inhibitory effect. Reverse
transcriptase-polymerase chain reaction (RT-PCR) showed that NRK-52E cells express cPLA2 and iPLA2 mRNAs, but not sPLA2. In the
mag-fura 2 fluorescence measurements, extracellular Mg2 + removal caused slight decrease in the intracellular free Mg2 + concentration
([Mg2 +]i) in the Na
+-free condition. The addition of Na+ caused a rapid decrease in [Mg2 +]i, indicating the presence of a Na
+-dependent
Mg2 + efflux pathway. The Na+-dependent [Mg2 +]i decrease was suppressed by MAFP and BEL. On the other hand, AA metabolite
inhibitors, nordihydroguaiaretic acid (NDGA) (50 AM), indomethacin (10 AM) and 17-octadecynoic acid (ODYA) (10 AM), enhanced the
Na+-dependent [Mg2 +]i decrease. Furthermore, the addition of exogenous AA (30 AM) enhanced the Na+-dependent [Mg2 +]i decrease,
which was significantly inhibited by imipramine (0.1 mM), a putative Na+/Mg2 +-exchanger inhibitor. These results suggest that extracellular
Mg2 + removal elevates AA release mediated mainly by iPLA2 and that AA upregulates the Na
+-dependent Mg2 + efflux in NRK-52E cells.
D 2003 Elsevier B.V. All rights reserved.Keywords: Arachidonic acid; Intracellular Mg2+; Kidney; Mag-fura 2; Phospholipase A21. Introduction differentiation and proliferation [4,5]. Recently, we reportedThe Mg2 + concentration in the body is regulated by renal
Mg2 + reabsorption. Most glomerular filtered Mg2 + is reab-
sorbed from the proximal tubule and thick ascending limb
[1,2]. The Mg2 + transport pathways are divided into two
types; a paracellular pathway and a transcellular pathway.
The latter includes a putative Mg2 + channel, Mg2 + pump,
and Na+/Mg2 +-exchanger, which also regulate the intracel-
lular free Mg2 + concentration ([Mg2 +]i). [Mg
2 +]i is an
essential cofactor for many enzymes [3], a modulator of
DNA and protein synthesis [4], and plays a role in cell0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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-independent Mg2 + efflux when incubated in the absence of
extracellular Mg2 + and that the former is predominant [6,7].
The regulatory mechanisms of [Mg2 +]i, however, have not
been fully clarified. The Na+-dependent Mg2 + transport is
inhibited by amiloride, quinidine, and imipramine and may
be regulated by protein kinase A, protein kinase C (PKC),
and protein kinase G depending on cell type [7–11].
The concentration of free ionized Mg2 + in the blood is
rigorously controlled within the physiological range (about
0.6 mM). A reduction of Mg2 + concentration increases the
levels of prostanoids in the plasma [12]. Furthermore, the
urinary excretion of arachidonic acid (AA) metabolites,
including prostaglandin E2, 6-keto-prostaglandin F1, and
thromboxane B2, was increased in rats maintained on a low
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ship between AA metabolism and Mg2 + homeostasis.
The present study was undertaken to examine whether
the extracellular Mg2 + concentration affects AA production
and whether AA is involved in the regulation of Na+-
dependent Mg2 + efflux measured in NRK-52E cells incu-
bated in the absence of Mg2 +. Our findings demonstrated
that NRK-52E cells express cytosolic phospholipase A2
(cPLA2) and Ca
2 +-independent phospholipase A2 (iPLA2)
mRNAs and that the decrease in extracellular Mg2 + con-
centration increases AA production. After extracellular
Mg2 + removal, the addition of Na+ induced a potent
[Mg2 +]i decrease which was mediated mainly by iPLA2
activation. The Na+-induced [Mg2 +]i decrease was en-
hanced by AA metabolite inhibitors and inhibited by imip-
ramine, a putative Na+/Mg2 +-exchanger inhibitor. This is
the first report showing that AA is involved in the upregu-
lation of the Na+-dependent Mg2 + efflux pathway.2. Materials and methods
2.1. Materials
Bromoenol lactone (BEL) and Dulbecco’s modified
Eagle’s medium (DMEM) were purchased from Sigma
(St. Louis, MO, USA). Indomethacin was from Wako Pure
Chemical Industries (Osaka, Japan). Mag-fura 2/acetoxy-
methyl ester (AM) and Pluronic F-127 were obtained from
Molecular Probes (Eugene, OR, USA). [3H]-Arachidonic
acid ([3H]-AA) was from PerkinElmer Life Sciences (Bos-
ton, MA, USA). Methyl arachidonyl fluorophosphonate
(MAFP), nordihydroguaiaretic acid (NDGA) and 17-octa-
decynoic acid (ODYA) were from Cayman Chemical Com-
pany (Ann Arbor, MI, USA). LY-311727 was a generous
gift from Eli Lilly (Indianapolis, IN, USA).
2.2. Cell culture
The NRK-52E cells were obtained from American Type
Culture Collection (Manassas, VA, USA). This cell line is
derived from the proximal tubule epithelium of normal rat
kidney. The cells were grown on 100-mm plastic culture
dishes (Corning, NY, USA) in DMEM supplemented with
5% fetal bovine serum, 0.14 mg/ml streptomycin sulfate and
0.07 mg/ml penicillin G potassium in a humidified environ-
ment of 5% CO2–95% air at 37 jC. All cells used in the
present experiments were cultured in 5 mMMg2 +-containing
DMEM for 1–2 days before use as described previously [7].
2.3. Measurement of AA and its metabolites
NRK-52E cells were grown on 24-well plates (Corning)
to sub-confluence for 2 days. The generation of AA and its
metabolites was analyzed as the release of [3H]-metabolites
from the membrane phospholipids. The cells were preincu-bated with DMEM containing [3H]-AA (0.5 ACi/well) for 24
h at 37 jC resulting in equilibrium incorporation of the [3H]-
AA into the phospholipids. The medium containing [3H]-AA
was removed from the cells, which were then washed three
times with Na+-free/Mg2 +-containing solution. We used four
solutions; a Na+-free/Mg2 +-containing solution contained
(in mM): 140 choline-Cl, 20 HEPES, 5.4 KCl, 0.4 KH2PO4,
5 MgCl2, and 10 glucose; a Na
+-containing/Mg2 +-contain-
ing solution was identical except for the replacement of
choline-Cl with NaCl; a Na+-containing/Mg2 +-free solution
was identical except for the replacement of choline-Cl with
NaCl and the omission of MgCl2; and a Na
+-free/Mg2 +-free
solution was identical except for the omission of MgCl2. The
pH of all solutions was adjusted to 7.4 with Tris. The cells
were preincubated with the Na+-free/Mg2 +-containing solu-
tion in the presence and absence of PLA2 inhibitors for 30
min, followed by incubation with the indicated solutions.
The [3H]-AA release was measured with a liquid scintillation
counter and the values are represented as dpm/Ag protein.
2.4. RNA isolation and reverse transcriptase-polymerase
chain reaction (RT-PCR)
Cells were grown on six-well plates (Corning) to sub-
confluence for 2 days. Total RNA was isolated using a
QuickPrep Total RNA Extraction Kit (Amersham Pharma-
cia Biotech, Piscataway, NJ, USA). RT-PCR was performed
with a TaKaRa RNA PCR Kit (AMV) Ver. 2.1 (Takara Bio,
Tokyo, Japan). Total RNA (1 Ag) was oligo-dT-primed in
the presence of the AMV reverse transcriptase XL (42 jC
for 30 min and heated at 99 jC for 5 min). PCR reactions
were performed in a 20-Al reaction volume of 3 Al cDNA
mixture, 1 PCR buffer containing 1.5 mM MgCl2, 200
AM of each dNTP, 400 nM of each primer, and 1 unit of the
TaKaRa Taq DNA polymerase. The DNA was denatured at
94 jC for 3 min prior to PCR cycling (30 cycles) at 94 jC
for 0.5 min (denaturation), 58 jC for 0.5 min (annealing),
and 72 jC for 1 min (extension). Following the last cycle,
elongation was extended for an additional 7 min at 72 jC
before refrigeration. The following primers were used:
cPLA2 (type IVA), 5V-GATTGTGCGACCTACGTTGC-3V
and 5V-CTACCCAATCGGCAAACATC-3V; iPLA2 (type
VIA), 5 V-AGAAGGGGTGTGCTGAATG-3 V and 5 V-
TGGGGCATGAGATCCTGAAGC-3V; and secretory PLA2
(sPLA2, type IIA), 5V-TGGCTCAATACAGGTCCAAG-3V
and 5V-TCATGAGTAACACAGCACCG-3V. The PCR prod-
ucts were visualized with ethidium bromide after electro-
phoretic separation on a 2% agarose gel. The cPLA2, iPLA2,
and sPLA2 primer pairs were designed to amplify fragments
of 387, 417, and 166 bp, respectively.
2.5. Measurement of intracellular free Mg2+ concentration
([Mg2+]i)
Cells were grown on glass slides to sub-confluence for
1–2 days. [Mg2 +]i was determined using a Mg
2 +-sensitive
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Na+-free/Mg2 +-containing solution in the presence of 2 AM
mag-fura 2 acetoxymethylester (mag-fura 2/AM, Molecular
Probes) and a detergent, Pluronic F127 (0.025%, w/v,
Molecular Probes), at 37 jC for 30 min. Then, the mag-
fura 2-loaded cells were washed twice with the dye-free
Na+-free/Mg2 +-containing solution and placed in a glass
cuvette. The mag-fura 2 fluorescence was monitored at 1-s
intervals using a dual-excitation wavelength spectrofluo-rometer (Hitachi F-2000, Tokyo, Japan) with excitation at
340 and 380 nm and emission at 495 nm. The ratio of the
two fluorescence emission intensities was stored for further
analysis. Bathing solution was perfused continuously at a
speed of 1.5 ml/min. Experiments were performed at 37 jC.
The [Mg2 +]i was calculated according to the formula of
Grynkiewicz et al. [14], using a dissociation constant (Kd) of
1.45 mM for the Mg2 +-mag-fura 2 complex. The maximum
(Rmax) and minimum (Rmin) ratios were determined for the
cells permeabilized with 5 AM ionomycin in the presence of
20 mM MgCl2 and 50 mM EDTA, respectively. The initial
rate of [Mg2 +]i decrease (AM/s) was estimated following
substitution from the Na+-free/Mg2 +-free solution to the
Na+-containing/Mg2 +-free solution.
2.6. Statistics
Results are presented as the meansF S.E. Differences
between groups were analyzed by one-way analysis of
variance (ANOVA), and correction for multiple comparison
was made using Tukey’s multiple comparison test and
Dunnett’s multiple comparison test. Where appropriate,
Student’s t-test was used. Significant differences were
assumed at P < 0.05.3. Results
3.1. Elevation of the release of AA and its metabolites by
extracellular Mg2+ removal
A low Mg2 + diet causes a decrease in the serum Mg2 +
concentration and increase in AA and prostanoid concen-
trations in the rat [12,13]. In the first part of this study, we
investigated the effect of extracellular Mg2 + removal on
the production and release of AA metabolites in NRK-52E
cells. Cells were cultured in 5 mM Mg2 +-containing
DMEM for 2 days to correspond with the conditions ofFig. 1. Removal of extracellular Mg2 + induces AA release. (A) NRK-52E
cells were cultured in DMEM containing [3H]-AA (0.5 ACi/well) for 24 h.
The cells were preincubated with Na+-free/Mg2 +-containing solution for 30
min, then incubated with Na+-containing/Mg2 +-free solution (open circle)
or Na+-free/Mg2 +-containing solution (closed circle) for the indicated
times. Extracellular release of AA and its metabolites was measured with a
liquid scintillation counter. n= 4. *P< 0.05 and **P< 0.01, significantly
different from 0 min. (B) The cells were incubated for 4 min in the presence
of Na+ and Mg2 +, in the presence of Na+ and absence of Mg2 +, in the
absence of Na+ and presence of Mg2 +, and in the absence of Na+ and Mg2 +
(hatched columns). Open column shows the solution that was collected just
before the replacement with the indicated solution. **P < 0.01, significantly
different from the value in the Na+-containing/Mg2 +-containing solution.
NS P > 0.05. (C) The cells were preincubated with the Na+-free/Mg2 +-
containing solution in the absence (control) and presence of PLA2
inhibitors, 10 AM LY-311727 (LY), 10 AM MAFP, or 10 AM BEL for 30
min, then incubated with either the Na+-free/Mg2 +-containing solution
(open columns) or the Na+-free/Mg2 +-free solution (hatched columns)
without (control) or with the indicated PLA2 inhibitor for 4 min. n= 4.
**P < 0.01, significantly different from control. NS P > 0.05.
Fig. 3. Na+-dependent [Mg2 +]i decrease in NRK-52E cells. (A, B)
Representative traces of [Mg2 +]i measurements are shown. The cells were
loaded with mag-fura-2, then placed in a glass cuvette containing the Na+-
free/Mg2 +-containing or the Na+-free/Mg2 +-free solution. The Na+-free/
Mg2 +-containing solution was changed to the Na+-free/Mg2 +-free solution
(A) or the Na+-free/Mg2 +-free solution was changed to the Na+-containing/
Mg2 +-free solution (B). (C) The initial rate of [Mg2 +]i decrease was
estimated following perfusion with the Na+-free/Mg2 +-free solution (Na)
A. Ikari et al. / Biochimica et Biophysica Acta 1618 (2003) 1–74the Mg2 + efflux measurement (see Section 3.3). [3H]-AA-
labeled cells were preincubated in Na+-free/Mg2 +-contain-
ing solution for 30 min. A subsequent change to Na+-
containing/Mg2 +-free solution induced the release of AA
and its metabolites in a time-dependent manner (Fig. 1A).
AA release remained unaltered upon continued incubation
in Na+-free/Mg2 +-containing solution. Mg2 + removal also
increased the AA metabolites release in the Na+-free
condition, whereas Na+ removal was without effect in the
presence of Mg2 + (Fig. 1B). The Mg2 + removal-induced
release of AA metabolites was virtually abolished by
MAFP (10 AM), a cPLA2 and iPLA2 inhibitor, and BEL
(10 AM), an irreversible iPLA2 inhibitor (Fig. 1C). On the
other hand, LY-311727 (10 AM), a selective sPLA2 inhib-
itor, did not inhibit the Mg2 + removal-induced AA release.
These inhibitors did not affect AA release in the presence
of extracellular Mg2 +.
3.2. Determination of cPLA2 and iPLA2 transcripts in NRK-
52E cells by RT-PCR
In the RT-PCR experiment, we used three sets of primers
that amplify partial cDNA fragments of cPLA2, iPLA2 and
sPLA2. Fig. 2 shows that cPLA2 and iPLA2 transcripts exist
in NRK-52E cells. However, a specific band for sPLA2 was
not detected in the cells. These results correspond to the
inhibitory effects (Fig. 1C), indicating that cPLA2 and
iPLA2 are mainly involved in Mg
2 + removal-induced re-
lease of AA metabolites.
3.3. Effects of PLA2 inhibitors on Na
+-dependent [Mg2+]i
decrease
In the second part of this study, we investigated the
involvement of AA (metabolites) in the Na+-induced
[Mg2 +]i decrease in NRK-52E cells incubated in the ab-
sence of extracellular Mg2 +. After loading with mag-fura 2,
the cells were incubated in a Na+-free/Mg2 +-free solution
and used for fluorescence measurements. Maintaining the
cells in DMEM containing 5 mM Mg2 + for 1–2 days
increased [Mg2 +]i from 0.37F 0.03 to 0.78F 0.02 mM
(n = 8–10). Mg2 +-loaded cells enabled us to detect Na+-Fig. 2. Detection of PLA2 mRNA by RT-PCR in NRK-52E cells. Total
RNAwas isolated from the NRK-52E cells cultured in 5 mM DMEM for 2
days. In lanes 1, 2 and 3, the primers for cPLA2, iPLA2 and sPLA2 were
used, respectively. Lane 4 shows a 100 bp DNA ladder.
or the Na+-containing/Mg2 +-free solution ( +Na). n= 6. ** P < 0.01,
significantly different from the value in the Na+-free/Mg2 +-free solution.induced Mg2 + efflux that was not observed in control cells
presumably because of detection limitations. Although the
[Mg2 +]i slightly decreased in the nominally Na
+- and Mg2 +-
free conditions, the addition of Na+ caused a rapid decrease
in [Mg2 +]i, resulting in a new steady state after 10 min (Fig.
3A and B). Calculation of initial rate of [Mg2 +]i decrease
following the change of solution revealed that the effect of
Na+ was significant. (Fig. 3C). On the other hand, Na+ did
not alter [Mg2 +]i when added in the presence of Mg
2 +
(initial rate of [Mg2 +]i decrease:  0.02F 0.01 AM/s,
n = 6). Fig. 4A shows that the Na+-stimulated [Mg2 +]i
Fig. 4. Effects of PLA2 and AA metabolite inhibitors on Na
+-dependent
[Mg2 +]i decrease. (A) The cells were preincubated with the Na
+-free/Mg2 +-
containing solution in the absence (control) and presence of 10 AM LY-
311727 (LY), 10 AM MAFP, or 10 AM BEL for 30 min. The initial rate of
[Mg2 +]i decrease was estimated following perfusion with the Na
+-
containing/Mg2 +-free solution. n= 6–16. *P < 0.05, significantly different
from control. NS P > 0.05. (B) The cells were preincubated with the Na+-
free/Mg2 +-containing solution in the absence (control) and presence of AA
metabolite inhibitors, 50 AM NDGA, 10 AM indomethacin (INDO), or 10
AM ODYA for 30 min. The initial rate was estimated following perfusion
with the Na+-containing/Mg2 +-free solution. n= 5–12. *P < 0.05, signifi-
cantly different from control.
Table 1
AA-sensitive Na+-dependent [Mg2 +]i decrease is inhibited by imipramine in NRK
Basal [Mg2 +]i (mM)
Control 0.76F 0.03 (7)
+ quinidine (0.1 mM) 0.77F 0.02 (4)
+ imipramine (0.1 mM) 0.75F 0.01 (5)
AA (30 AM) 0.76F 0.01 (6)
+ imipramine (0.1 mM) 0.75F 0.02 (6)
Values are meansF S.E.; number of experiments is in parenthesis. The cells w
quinidine or imipramine for 10 min. After the cells were placed in a glass cuvette c
Na+-containing/Mg2 +-free solution as shown in Fig. 3B. The basal [Mg2 +]i was
Initial rate of [Mg2 +]i decrease was estimated following perfusion with the Na
+-co
represented as percentage of control.
**P< 0.01, significantly different from control.
§§ P < 0.01,significantly different from AA.
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following pretreatment with MAFP (10 AM) and BEL (10
AM), but not LY-311727 (10 AM). These inhibitors did not
significantly affect the basal [Mg2 +]i measured immediately
before changing to Na+-containing/Mg2 +-free solution (con-
trol: 0.76F 0.03 mM; MAFP: 0.76F 0.02 mM; BEL:
0.77F 0.03 mM, and LY-311727: 0.76F 0.02 mM, n = 4–
9, P>0.05 vs. control). There were no synergistic or additive
effects by co-treatment with MAFP and BEL (initial rate of
[Mg2 +]i decrease of MAFP:  0.18F 0.02, BEL:  0.18F
0.01, and co-treatment of MAFP and BEL:  0.16F 0.03
AM/s, respectively, n = 4–8, P>0.05). The inhibitory effects
of MAFP and BEL are consistent with effects on AA
release (Fig. 1C), indicating that iPLA2-mediated AA pro-
duction is involved in upregulation of the Na+-dependent
Mg2 + efflux.
3.4. Effects of AA metabolite inhibitors on Na+-dependent
[Mg2+]i decrease
The cells were preincubated with NDGA (50 AM), a
lipoxygenase (LOX) inhibitor, indomethacin (10 AM), a
cyclooxygenase (COX) inhibitor, or ODYA (10 AM), a
cytochrome P450-dependent epoxygenase and N-hydroxy-
lase inhibitor. All these chemicals enhanced the Na+-depen-
dent [Mg2 +]i decrease (Fig. 4B) without affecting the basal
[Mg2 +]i (control: 0.76F 0.03 mM; NDGA: 0.79F 0.01
mM; indomethacin: 0.78F 0.01 mM and ODYA: 0.75F
0.02 mM, n = 5–7, P> 0.05 vs. control). These results
suggest that an increase in AA concentration caused by
inhibition of AA metabolism enhanced the Na+-dependent
[Mg2 +]i decrease.
3.5. Effects of exogenous AA and Na+/Mg2+-exhanger
inhibitors on Na+-dependent [Mg2+]i decrease
So far, Na+-dependent Mg2 + transport has been shown to
be inhibited by the putative Na+/Mg2 +-exchanger inhibitors,
imipramine and quinidine in MDCK cells [15] and ferret red
cells [16], imipramine in rat hepatocytes [8] and human red-52E cells
Initial rate (AM/s) Control (%)
0.37F 0.02 100
0.39F 0.01 105.9
0.13F 0.01** 36.2
0.55F 0.03** 148.2
0.28F 0.02§§ 76.4
ere preincubated with the Na+-free/Mg2 +-containing solution containing
ontaining the Na+-free/Mg2 +-free solution, the solution was changed to the
measured just before changing to the Na+-containing/Mg2 +-free solution.
ntaining/Mg2 +-free solution. The effects of chemicals on the initial rate are
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We found that the Na+-dependent [Mg2 +]i decrease was
inhibited by imipramine (0.1 mM), but not by quinidine (0.1
mM) in NRK-52E cells (Table 1). On the other hand, the
addition of exogenous AA (30 AM) enhanced the Na+-
dependent [Mg2 +]i decrease. The AA-induced [Mg
2 +]i
decrease was significantly inhibited by imipramine. Wolf
et al. [19] reported that an AA-activated and imipramine-
inhibited Mg2 + efflux pathway exists in mouse ascites cells.
However, they showed that the Mg2 + efflux pathway is
activated by AA metabolites, but not by AA itself. Our
results indicate that a putative Na+/Mg2 +-exchanger in
NRK-52E cells is upregulated by AA and inhibited by
imipramine.4. Discussion
About 80% of the serum Mg2 + is filtered through the
glomerular membrane (for review see Ref. [20]) and most
is reabsorbed in the proximal tubule, including the con-
voluted and straight portions, and the thick ascending
limb. The regulatory mechanisms of Mg2 + transport have
been well studied in the thick ascending limb. The
reabsorption of Mg2 + within the proximal tubule and the
thick ascending limb is suggested to be mainly mediated
by a paracellular pathway. Some investigators postulated
an additional transcellular pathway that is regulated by
hormones and non-hormonal factors [1,2]. To confirm the
functions of transcellular Mg2 + transporters in physiolog-
ical and pathological conditions, regulatory mechanisms of
[Mg2 +]i were studied. Recently, we reported that Na
+-
dependent Mg2 + efflux is observed in renal epithelial
NRK-52E cells incubated in Mg2 +-free conditions. In
the present study, we examined the effect of extracellular
Mg2 + removal on AA production and the involvement of
AA in the regulation of the Na+-dependent Mg2 + efflux
pathway.
AA is a cis-polyunsaturated fatty acid and ubiquitously
present in the plasma membrane. It is normally linked
covalently to other molecules in the membrane to form
phospholipids, but can be liberated by activation of cellular
phospholipases. We report for the first time that extracellular
Mg2 + removal elevates AA release in NRK-52E cells.
Alzola et al. [21] reported that ATP activates AA release
that is inhibited by 5 mM Mg2 + in rat submandibular
glands. They suggested that the activation of nonspecific
cation channels coupled to purinoceptors increases the AA
release. In our study, extracellular Mg2 + removal might
have cancelled the inhibition of the nonspecific cation
channels to increase AA release.
Three types of phospholipase A2, iPLA2, cPLA2, and
sPLA2, are present in the rat kidney [22]. We showed that
iPLA2 and cPLA2 exist in NRK-52E cells by RT-PCR (Fig.
2). iPLA2 is an 85-kDa protein that is inhibited by BEL
[23,24]. The functions of iPLA2 have not been fully exploredand its physiological and pathological relevance remains
under investigation. On the contrary, cPLA2 has been
reported to require micromolar Ca2 + concentrations in order
to translocate to the plasma membrane on activation but does
not require Ca2 + for its catalytic activity. In cPLA2-knockout
mice, basal urinary prostaglandin E2 excretion was reduced,
suggesting that cPLA2 is involved in the regulation of Na
+
and water reabsorption under physiological conditions [25].
In our experimental conditions, however, Mg2 + removal did
not significantly elevate the intracellular free Ca2 + concen-
tration [7]. Furthermore, the Na+-dependent [Mg2 +]i de-
crease was inhibited by BEL and MAFP (Fig. 4) and
because the combination of BEL and MAFP did not give
additive or synergistic effects, both inhibitors most probably
act on the same target. Therefore, although we cannot
completely exclude the involvement of cPLA2 and other
molecules, iPLA2 appears to be the predominant AA-pro-
ducing enzyme activated in response to a decrease in the
extracellular Mg2 + concentration in NRK-52E cells.
Unesterified or free AA has been shown to modulate the
activity of a variety of ion transporters (for review see Ref.
[26]). AA modulation can occur by both direct and indirect
mechanisms. Many indirect effects are apparently mediated
by AA metabolites generated by COX, LOX, or cytochrome
P450-dependent epoxygenase and N-hydroxylase [27–29].
In other cases, however, AA has also been shown to act
directly on channel proteins [30,31]. We found that the Na+-
dependent [Mg2 +]i decrease occurred in the absence of
extracellular Mg2 +, a condition that also increased the
production of AA and its metabolites. Furthermore, the
Na+-dependent [Mg2 +]i decrease is upregulated by AA
itself, but not by its metabolites (Fig. 4 and Table 1). At
present, we do not know how AA upregulates Na+-depen-
dent Mg2 + efflux. AA has been reported to regulate PKC in
rat hippocampal [32] and chondrocytes [33]. We recently
reported that a PKC inhibitor diminishes the Na+-dependent
[Mg2 +]i decrease in NRK-52E cells [7], suggesting that AA-
elicited PKC activation may be involved in upregulation of
the Na+-dependent Mg2 + efflux pathway.
In isolated porcine thick ascending limb cells, Dai and
Quamme [34] reported that Mg2 + uptake was inhibited by
Ca2 + channel blockers, although it was not inhibited by
quinidine, suggesting that the Mg2 + influx pathway is a
channel with close homology to known Ca2 + channels.
On the other hand, the presence of a putative Na+-
dependent Mg2 + transporter has been reported in various
mammalian cells [16,17,35,36]. This transporter is com-
monly inhibited by amiloride, quinidine and imipramine.
Our results show that the Na+-dependent [Mg2 +]i decrease
is inhibited by imipramine, but not by quinidine in NRK-
52E cells. Therefore, we suggest that the Na+-dependent
Mg2 + efflux pathway in NRK-52E cells is a novel
pathway that is sensitive to the extracellular Na+ concen-
tration and imipramine.
In conclusion, we have found that extracellular Mg2 +
removal elevated AA production by the activation of iPLA2
A. Ikari et al. / Biochimica et Biophysica Acta 1618 (2003) 1–7 7in renal epithelial NRK-52E cells, and that AA upregulates
Na+-dependent Mg2 + efflux which is inhibited by imipra-
mine. There is a possibility that the Na+-dependent Mg2 +
efflux pathway is involved in reabsorption of Mg2 + as well
as in control of intracellular Mg2 + homeostasis because it is
activated by changing the extracellular Mg2 + concentration.
Also, AA may play an important role in regulating trans-
cellular Mg2 + reabsorption in Mg2 + deficiency.Acknowledgements
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